Premium
Anti‐inflammatory Strategies to Prevent Diabetic Cardiovascular Disease
Author(s) -
Jialal I,
Devaraj S
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.105
Subject(s) - pioglitazone , medicine , inflammation , proinflammatory cytokine , diabetes mellitus , metformin , angiotensin receptor blockers , disease , pharmacology , type 2 diabetes , bioinformatics , renin–angiotensin system , endocrinology , blood pressure , biology
Diabetes is a proinflammatory state and inflammation is crucial in the genesis of vascular complications. While there are many anti‐inflammatory strategies, most of which have been shown to reduce inflammation in diabetes, there is sparse data on reduction in cardiovascular events (CVEs). To date, the only anti‐inflammatory strategies that have been shown to reduce CVE in diabetes include statins, angiotensin receptor blockers, metformin, and pioglitazone. We also discuss the role of novel emerging therapies.